Oncology On targeted radiotherapeutics, with Marc Hedrick Dr Marc Hedrick, president and CEO of Plus Therapeutics, discusses developing targeted radiotherapeutics.
Oncology Advances in breast cancer: What’s new from ESMO 2025 ESMO 2025 showcased the breadth and urgency of breast cancer research, which remains one of the most diagnosed malignancies worldwide.
Oncology ESMO25: Acceleration, accessibility, and accuracy, with Barr... At ESMO25, pharmaphorum spoke with Barry Vucsko, Senior VP of Strategic Development, Agency Services, for the EVERSANA Oncology Centre of Excellence.
Oncology ESMO25: Transforming the cancer immunotherapy field, with Po... Onsite at ESMO 2025 in Berlin, pharmaphorum spoke with Poolbeg's Liam Tremble about their work on CRS in relapsed/refractory multiple myeloma.
Oncology ESMO25: On getting ahead of cancer, with J&J's Henar Hevia &... In conversation with Johnson & Johnson experts at ESMO 2025, discussing T-cell-redirecting bispecific antibodies and the future of immunotherapy.
News NHS staff 'feel unprepared for digital transformation' A survey of NHS workers has found that almost two-thirds feel they are unprepared for the digital transformation objectives of the 10-Year Plan.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
